Profile data is unavailable for this security.
About the company
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.
- Revenue in AUD (TTM)278.45m
- Net income in AUD-258.82m
- Incorporated2005
- Employees900.00
- LocationMayne Pharma Group Ltd1538 Main North RdADELAIDE 5106AustraliaAUS
- Phone+61 88209-2666
- Fax+61 88281-0284
- Websitehttp://www.maynepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmAust Limited | 1.85m | -7.79m | 93.46m | 52.00 | -- | 10.53 | -- | 50.49 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
| EZZ Life Science Holdings Ltd | 43.71m | 3.47m | 101.71m | -- | 28.13 | 6.39 | 26.85 | 2.33 | 0.0814 | 0.0814 | 1.02 | 0.3582 | 2.48 | 9.63 | 13.51 | -- | 19.69 | 21.22 | 24.85 | 29.19 | 74.77 | 55.31 | 7.94 | 9.11 | 3.61 | 293.27 | 0.0195 | 13.08 | 147.26 | -- | 176.57 | -- | -- | -- |
| Recce Pharmaceuticals Ltd | 6.81m | -11.32m | 103.12m | -- | -- | 177.32 | -- | 15.14 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Vita Life Sciences Limited | 74.16m | 9.08m | 128.59m | 124.00 | 13.73 | 2.96 | 13.41 | 1.73 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
| Biome Australia Ltd | 10.24m | -2.86m | 132.47m | 30.00 | -- | 60.71 | -- | 12.93 | -0.0141 | -0.0141 | 0.0506 | 0.0101 | 1.37 | 1.93 | 6.04 | 341,434.70 | -38.27 | -- | -74.60 | -- | 61.29 | -- | -27.97 | -- | 0.9514 | -15.92 | 0.4032 | -- | 73.58 | -- | 32.20 | -- | -- | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 398.15m | 900.00 | -- | 0.6941 | -- | 1.43 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 651.61m | 1.00 | -- | 12.27 | -- | 3,251.89 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 763.69m | 16.00 | 26.18 | 4.28 | 24.52 | 8.75 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 18 Sep 2023 | 4.36m | 5.12% |
| Lazard Asset Management Pacific Co.as of 13 Jun 2023 | 4.24m | 4.99% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 2.82m | 3.31% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.21m | 1.42% |
| Vanguard Investments Australia Ltd.as of 30 Jun 2024 | 1.18m | 1.39% |
| Investors Mutual Ltd.as of 28 Jun 2024 | 836.00k | 0.98% |
| DFA Australia Ltd.as of 31 May 2024 | 648.46k | 0.76% |
| UBS AG (Investment Management)as of 14 Mar 2024 | 640.13k | 0.75% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 555.30k | 0.65% |
| UBS Asset Management (Australia) Ltd.as of 14 Mar 2024 | 478.45k | 0.56% |
